



Final Appraisal Recommendation

Sunitinib (Sutent[®])
Submission by:
Pfizer Ltd

Advice No: 1111 – September 2011

Recommendation of AWMSG

Sunitinib (Sutent[®]) is recommended for use within NHS Wales for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults. Experience with sunitinib as a first-line treatment is limited.

AWMSG is of the opinion that sunitinib (Sutent[®]) is not suitable for shared care within NHS Wales for the above indication.

Additional notes:

The AWMSG recommendation has been based on an approved patient access scheme.

In reaching this recommendation AWMSG took account of the [AWMSG Secretariat Assessment Report](#), the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, [clinical expert opinion](#), lay/patient/carer perspective and discussions at AWMSG.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: